EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Alberto Sobrero, Joan Maurel, Louis Fehrenbacher, +17

Journal of Clinical Oncology

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

Eric Van Cutsem, István Láng, G D’Haens, +7

Journal of Clinical Oncology

Surgical OncologyCancer ManagementPathologyGastrointestinal OncologyMetronomic Therapy +18

Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer

Josep Tabernero, Eric Van Cutsem, Eduardo Díaz‐Rubio, +11

Journal of Clinical Oncology

Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase

Angelina J. Lay, Xing‐Mai Jiang, O. Kisker, +4

Nature

Cancer ResearchSignal TransductionAngiogenesisReceptor Tyrosine KinasePathology +8

Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model.

O. Kisker, C.-M. Becker, Daniela Prox, +8

PubMed

ImmunologyContinuous AdministrationPharmacotherapyBiomedical EngineeringBolus Administration +14

Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study

E. Rubio, Josep Tabernero, Eric Van Cutsem, +7

Journal of Clinical Oncology

Surgical OncologyImmunologyPathologyFirst-line TreatmentImmunotherapy +16

A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells

Anthony S. Don, O. Kisker, Pierre J. Dilda, +7

Cancer Cell

AngiogenesisAngiogenic Endothelial CellsBiochemistryMitochondrial FunctionNatural Sciences +8

Vitamin D Binding Protein-Macrophage Activating Factor (DBP-maf) Inhibits Angiogenesis and Tumor Growth in Mice

O. Kisker, Shinya Onizuka, Christian M. Becker, +8

Neoplasia

Therapeutic Efficacy of Endostatin Exhibits a Biphasic Dose-Response Curve

Ilhan Celik, Oǧuzkan Sürücü, Carsten Dietz, +6

Cancer Research

Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data

Sabine Tejpar, Marc Peeters, Yves Humblet, +7

Journal of Clinical Oncology

Phase I/ii StudyPathologyPharmacotherapyDermatologyOncology +16